A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1 alpha and VEGF expressions
Por:
Martinez-Garcia, MA, Riveiro-Falkenbach, E, Rodriguez-Peralto, JL, Nagore, E, Martorell-Calatayud, A, Campos-Rodriguez, F, Farre, R, Blasco, LH, Roca, JB, Vives, EC, Sanchez-de-la-Torre, A, Capa, JA, Montserrat, JM, Almendros, I, Perez-Gil, A, Nuno, VC, Cano-Pumarega, I, Penafiel, JC, Cambriles, TD, Mediano, O, Arias, JD, Gozal, D
Publicada:
1 dic 2017
Resumen:
Melanoma is a highly prevalent cancer that is associated with substantial mortality. Although clinical staging procedures can serve as relatively robust prognostic indicators, we aimed to determine whether assessments of the abundance of hypoxia inducible factor-1 alpha (HIF-1 alpha) or vascular endothelial growth factor (VEGF) in postexcisional melanoma tumor tissues may enable more accurate determination of tumor aggressiveness. We carried out a multicenter prospective study, in which we systematically evaluated 376 consecutive patients diagnosed with melanoma, and performed histochemical assessments for both HIF-1 alpha and VEGF immunoreactivity in the tumor biopsies. Multivariate analyses showed that higher HIF-1 alpha expression, but not high VEGF, were associated significantly and independently with increased tumor aggressiveness as derived from several well-established aggressiveness criteria. A limitation of this study was that this was a descriptive prospective study lacking a post-hoc verification arm. Thus, the presence of increased numbers of positively labeled HIF-1 alpha cells in melanoma tumors may potentially serve as an indicator of tumor phenotype and prognosis, and accordingly guide therapy. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
Filiaciones:
Martinez-Garcia, MA:
Hosp Univ Politecn La Fe, Dept Resp, Valencia, Spain
Ctr Investigac Biomed Red Enfermedades Resp, Barcelona, Spain
Riveiro-Falkenbach, E:
Univ Complutense, Sch Med, Dept Pathol, Inst i + 12,Hosp Univ 12 Octubre, Madrid, Spain
Rodriguez-Peralto, JL:
Univ Complutense, Sch Med, Dept Pathol, Inst i + 12,Hosp Univ 12 Octubre, Madrid, Spain
Nagore, E:
Inst Valenciano Oncol, Dept Dermatol, Valencia, Spain
Martorell-Calatayud, A:
Hosp Manises, Dept Dermatol, Valencia, Spain
Campos-Rodriguez, F:
Hosp Univ Valme, Dept Resp, Seville, Spain
Farre, R:
Ctr Investigac Biomed Red Enfermedades Resp, Barcelona, Spain
Blasco, LH:
Hosp Gen Univ Alicante, Dept Resp, Alicante, Spain
Miguel Hernandez Univ, Dept Med, Elche, Spain
Roca, JB:
Hosp Gen Univ Alicante, ISABIAL, Dept Dermatol, Alicante, Spain
Miguel Hernandez Univ, Dept Med, Elche, Spain
Vives, EC:
Hosp San Juan Alicante, Dept Resp, Alicante, Spain
Sanchez-de-la-Torre, A:
Ctr Investigac Biomed Red Enfermedades Resp, Barcelona, Spain
Hosp Univ Arnau Vilanova & Santa Maria, Grp Translat Res Resp Med, Dept Resp, IRBLleida, Lleida, Spain
Capa, JA:
Ctr Investigac Biomed Red Enfermedades Resp, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Dept Resp, Badalona, Spain
Montserrat, JM:
Ctr Investigac Biomed Red Enfermedades Resp, Barcelona, Spain
Hosp Clin IDIBAPS, Dept Resp, Barcelona, Spain
Almendros, I:
Univ Barcelona, Biophys & Bioengn Unit, Dept Med & Hlth Sci, Barcelona, Spain
Perez-Gil, A:
Hosp Valme, Dept Dermatol, Seville, Spain
Nuno, VC:
Hosp Univ Cruces, Dept Resp, Bilbao, Spain
Cano-Pumarega, I:
Hosp Univ Getafe, Dept Resp, Madrid, Spain
Penafiel, JC:
Ctr Investigac Biomed Red Enfermedades Resp, Barcelona, Spain
Hosp Univ S Pedro Alcantara, Dept Resp, Caceres, Spain
Cambriles, TD:
Hosp 12 Octubre, Dept Resp, Madrid, Spain
Mediano, O:
Ctr Investigac Biomed Red Enfermedades Resp, Barcelona, Spain
Hosp Univ Guadalajara, Dept Resp, Guadalajara, Spain
Arias, JD:
Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
Gozal, D:
Univ Chicago, Pritzker Sch Med, Div Biol Sci, Dept Pediat, Room 4100,900 E 57th St,Mailbox 4, Chicago, IL 60637 USA
|